Your browser doesn't support javascript.
loading
Hodgkin lymphoma detection and survival: findings from the Haematological Malignancy Research Network.
Lamb, Maxine Je; Roman, Eve; Howell, Debra A; Kane, Eleanor; Bagguley, Timothy; Burton, Cathy; Patmore, Russell; Smith, Alexandra G.
Afiliação
  • Lamb MJ; Research Fellow, Epidemiology & Cancer Statistics Group (ECSG), Department of Health Sciences, University of York, York, UK maxine.lamb@york.ac.uk.
  • Roman E; Professor, Epidemiology & Cancer Statistics Group (ECSG), Department of Health Sciences, University of York, York, UK.
  • Howell DA; Senior Research Fellow, Epidemiology & Cancer Statistics Group (ECSG), Department of Health Sciences, University of York, York, UK.
  • Kane E; Research Fellow, Epidemiology & Cancer Statistics Group (ECSG), Department of Health Sciences, University of York, York, UK.
  • Bagguley T; Data Analyst, Epidemiology & Cancer Statistics Group (ECSG), Department of Health Sciences, University of York, York, UK.
  • Burton C; Consultant Haematologist, Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
  • Patmore R; Consultant Haematologist, Queen's Centre for Oncology and Haematology, Hull and East Yorkshire Hospitals, Cottingham, UK.
  • Smith AG; Reader, Epidemiology & Cancer Statistics Group (ECSG), Department of Health Sciences, University of York, York, UK.
BJGP Open ; 2019 Dec 10.
Article em En | MEDLINE | ID: mdl-31822492
BACKGROUND: Hodgkin lymphoma is usually detected in primary care with early signs and symptoms, and is highly treatable with standardised chemotherapy. However, late presentation is associated with poorer outcomes. AIM: To investigate the relationship between markers of advanced disease, emergency admission, and survival following a diagnosis of classical Hodgkin lymphoma (CHL). DESIGN & SETTING: The study was set within a sociodemographically representative UK population-based patient cohort of ~4 million, within which all patients were tracked through their care pathways, and linked to national data obtained from Hospital Episode Statistics (HES) and deaths. METHOD: All 971 patients with CHL newly diagnosed between 1 September 2004-31 August 2015 were followed until 18th December 2018. RESULTS: The median diagnostic age was 41.5 years (range 0-96 years), 55.2% of the patients were male, 31.2% had stage IV disease, 43.0% had a moderate-high or high risk prognostic score, and 18.7% were admitted via the emergency route prior to diagnosis. The relationship between age and emergency admission was U-shaped: more likely in patients aged <25 years and ≥70 years. Compared to patients admitted via other routes, those presenting as an emergency had more advanced disease and poorer 3-year survival (relative survival 68.4% [95% confidence interval {CI} = 60.3 to 75.2] versus 89.8% [95% CI = 87.0 to 92.0], respectively [P<0.01]). However, after adjusting for clinically important prognostic factors, no difference in survival remained. CONCLUSION: These findings suggest that CHL survival as a whole could be increased by around 4% if the cancer in patients who presented as an emergency had been detected at the same point as in other patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article